[
Abida, W., Patnaik, A., Campbell, D., Shapiro, J., Bryce, A. H., McDermott, R., Sautois, B., Vogelzang, N. J., Bambury, R. M., Voog, E. et al. (2020). Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J. Clin. Oncol., 38 (32), 3763–3772.10.1200/JCO.20.01035765502132795228
]Search in Google Scholar
[
Albers, P., Bögemann, M., Machtens, S., Merseburger, A. S., Schostak, M., Steuber, T., Wulfung, C., De Santis, M. (2020). Therapie des meta-stasierten Prostatakarzinoms im Wandel — neue Daten und offene Fragen. Der Urologe A., 59 (3), 307–317.10.1007/s00120-019-01072-031781782
]Search in Google Scholar
[
Amsberg von G., Merseburger, A. S. (2020). Therapie des metastasierten kastrationsresistenten Prostatakarzinoms. Urologe A., 59 (6), 673–680.10.1007/s00120-020-01187-932274540
]Search in Google Scholar
[
Angelergues, A., Efstathiou, E., Gyftaki, R., Wysocki, P. J., Lainez, N., Gonzalez, I., Castellano, D. E., Ozguroglu, M., Carbonero, I. G., Flechon, A. et al. (2018). Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents. Clin. Genitourin Cancer, 16 (4), e777–e784.10.1016/j.clgc.2018.02.01629550200
]Search in Google Scholar
[
Antonarakis, E. S., Piulats, J. M., Gross-Goupil, M., Goh, J., Ojamaa, K., Hoimes, C. J., Vaishampayan, U., Berger, R., Sezer, A., Alanko, T. et al. (2020). Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: Multicohort, open-label phase II KEYNOTE-199 study. J. Clin. Oncol., 38 (5), 395–405.10.1200/JCO.19.01638718658331774688
]Search in Google Scholar
[
Armstrong, A. J., Szmulewitz, R. Z., Petrylak, D. P., Holzbeierlein, J., Villers, A., Azad, A., Alcaraz, A., Alekseev, B., Iguchi, T., Shore, N. D. et al. (2019). ARCHES: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J. Clin. Oncol., 37 (32), 2974–2986.10.1200/JCO.19.00799683990531329516
]Search in Google Scholar
[
Attard, G., Borre, M., Gurney, H., Loriot, Y., Andresen-Daniil, C., Kalleda, R., Pham, T., Taplin, M. E. (2018). Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment. J. Clin. Oncol., 36 (25), 2639–2646.10.1200/JCO.2018.77.9827611840530028657
]Search in Google Scholar
[
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014). Enzalutamide in metastatic prostate cancer before chemotherapy. New Engl. J. Med., 371 (5), 424–433.10.1056/NEJMoa1405095441893124881730
]Search in Google Scholar
[
Boevé, L. M. S., Hulshof, M. C. C. M., Vis, A. N., Zwinderman, A. H., Twisk, J. W. R., Witjes, W. P. J. Delaere, K. P. J., van Moorselaar, R. J. A., Verhage, P. C. M. S., van Andel, G. (2019). Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: Data from the HORRAD trial. Eur. Urol., 75 (3), 410–418.10.1016/j.eururo.2018.09.00830266309
]Search in Google Scholar
[
Caffo, O., Bria, E., Giorgi, U. D., Tucci, M., Galli, L., Fratino, L., Rosseti, S., Iacovelli, R., Re, G. R., Mosillo, C. et al. (2017). Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: Final analysis from a multicenter Italian study. J. Clin. Oncol., 35 (15), 5030.10.1200/JCO.2017.35.15_suppl.5030
]Search in Google Scholar
[
Chi, K. N., Agarwal, N., Bjartell, A., Chung, B. H., Pereira de Santana Gomes, A. J., Given, R., Juárez Soto, Á., Merseburger, A. S., Özgüroğlu, M., Uemura, H. et al. (2019). Apalutamide for metastatic, castration-sensitive prostate cancer. New Engl. J. Med., 381 (1), 13–24.10.1056/NEJMoa1903307
]Search in Google Scholar
[
Chi, K. N., Protheroe, A., Rodríguez-Antolín, A., Facchini, G., Suttman, H., Matsubara, N., Ye, Z., Keam, B., Damião, R., Li, T., McQuarrie, K. et al. (2018). Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): An international, randomised phase 3 trial. Lancet Oncol., 19 (2), 194–206.10.1016/S1470-2045(17)30911-7
]Search in Google Scholar
[
Clarke, N., Wiechno, P., Alekseev, B., Sala, N., Jones, R., Kocak, I., Chiuri, V. E., Jassem, J., Fléchon, A., Redfern, C. et al. (2018). Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol., 19 (7), 975–986.10.1016/S1470-2045(18)30365-6
]Search in Google Scholar
[
Cornford, P., Bellmunt, J., Bolla, M., Briers, E., De Santis, M., Gross, T., Henry, A. M., Joniau, S., Lam, T. B., Mason, M. D. et al. (2017). EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of relaps g, metastatic, and castration-resistant prostate cancer. Eur. Urol., 71 (4), 630–642.10.1016/j.eururo.2016.08.002
]Search in Google Scholar
[
Davis, I. D., Martin, A. J., Stockler, M. R., Begbie, S., Chi, K. N., Chowdhury, S., Coskinas, X., Frydenberg, M., Hague, W. E., Horvath, L. G. et al. (2019). Enzalutamide with standard first-line therapy in metastatic prostate cancer. New Engl. J. Med., 381 (2), 121–131.10.1056/NEJMoa190383531157964
]Search in Google Scholar
[
De Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B. J., Saad, F. et al. (2011). COU-AA-301 Investigators. Abiraterone and increased survival in meta-static prostate cancer. New Engl. J. Med., 364 (21), 1995–2005.10.1056/NEJMoa1014618
]Search in Google Scholar
[
De Bono, J. S., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D. et al. (2020a). Olaparib for meta-static castration-resistant prostate cancer. New Engl. J. Med., 382 (22), 2091–2102.10.1056/NEJMoa191144032343890
]Search in Google Scholar
[
De Bono, J. S., Mehra, N., Higano, C. S., Saad, F., Buttigliero, C., Mata, M., Chen, H. C., Healy, C. G., Paccagnella, M. L., Czibere, A. et al. (2020b). TALAPRO- 1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC) — First interim analysis (IA). J. Clin. Oncol., 38 (6), 119.10.1200/JCO.2020.38.6_suppl.119
]Search in Google Scholar
[
De Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J. P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L. et al. (2010). Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet, 376 (9747), 1147–1154.10.1016/S0140-6736(10)61389-X
]Search in Google Scholar
[
Dienstmann, R., Dong, F., Borger, D., Dias-Santagata, D., Ellisen, L. W., Le, L. P., Iafrate, A. J. (2014). Standardized decision support in next generation sequencing reports of somatic cancer variants. Mol. Oncol., 8 (5), 859–873.10.1016/j.molonc.2014.03.021552852724768039
]Search in Google Scholar
[
Eisenberger, M., Hardy-Bessard, A. C., Kim, C. S., Géczi, L., Ford, D., Mourey, L., Carles, J., Parente, P., Font, A., Kacso, G. et al. (2017). Phase III study comparing a reduced dose of cabazitaxel (20 mg/m2) and the currently approved dose (25 mg/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA. J. Clin. Oncol., 35 (28), 3198–3206.10.1200/JCO.2016.72.107628809610
]Search in Google Scholar
[
Fendler, W. P., Weber, M., Iravani, A., Hofman, M. S., Calais, J., Czernin, J., Ilhan, H., Saad, F., Small, E. J., Smith, M. R. et al. (2019). Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin. Cancer Res., 25 (24), 7448–7454.10.1158/1078-0432.CCR-19-105031511295
]Search in Google Scholar
[
Fizazi, K., Shore, N. D., Tammela, T., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Kuss, I. et al. (2020). Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC). J. Clin. Oncol., 38 (15), 5514.10.1200/JCO.2020.38.15_suppl.5514
]Search in Google Scholar
[
Folkmanis, K., Eglītis, J., Jakubovskis, M., Lietuvietis, V., Folkmane, I, Isajevs, S. (2021a). CD63 and DNA mismatch repair protein expression in prostate cancer. Proc. Latvian Acad. Sci., Section B, 75 (3), 180–185.10.2478/prolas-2021-0027
]Search in Google Scholar
[
Folkmanis, K., Junk, E., Merdane, E., Folkmanis, V., Folkmane, I., Isajevs, S. (2021b). New kids on the block” — the game changers. The role of immune check point blockade in personalised treatment of prostate, urinary bladder, and kidney cancer. Proc. Latvian Acad. Sci., Section B, 75 (3), 149–157.10.2478/prolas-2021-0024
]Search in Google Scholar
[
Gravis, G., Boher, J. M., Joly, F., Soulié, M., Albiges, L., Priou, F., Latorzeff, I., Delva, R., Krakowski, I., Laguerre, B. et al. (2016). Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: Impact of metastatic burden and long-term survival analysis of the randomized Phase 3 GETUG-AFU15 Trial. Eur. Urol., 70 (2), 256–262.10.1016/j.eururo.2015.11.005
]Search in Google Scholar
[
Gravis, G., Fizazi, K., Joly, F., Oudard, S., Priou, F., Esterni, B., Latorzeff, I., Delva, R., Krakowski, I., Laguerre, B. et al. (2013). Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): A randomised, open-label, phase 3 trial. Lancet Oncol., 14 (2), 149–158.10.1016/S1470-2045(12)70560-0
]Search in Google Scholar
[
Gundem, G., Van Loo, P., Kremeyer, B., Alexandrov, L. B., Tubio, J. M. C., Papaemmanuil, E. Brewer, D. S., Kallio, H. M. L., Högnäs, G., Annala, M. et al. (2015). Nature, 520, 353–357.10.1038/nature14347441303225830880
]Search in Google Scholar
[
Hussain, M., Fizazi, K., Saad, F., Rathenborg, P., Shore, N., Ferreira, U., Ivashchenko, P., Demirhan, E., Modelska, K., Phung, D., Krivoshik, A., Sternberg, C. N. (2018). Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. New Engl. J. Med., 378 (26), 2465–2474.10.1056/NEJMoa1800536828803429949494
]Search in Google Scholar
[
Hussain, M., Mateo, J., Fizazi, K., Saad, F., Shore, N. D., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2019). LBA12_PRPROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. Ann. Oncol., 30 (5), 881–882.10.1093/annonc/mdz394.039
]Search in Google Scholar
[
Khalaf, D., Annala, M., Finch D. L., Oja, C. C., Vergidis, J., Zulfiqar, M., Sunderland, K., Beja, K., Vanderkhove, G. R., Gleave, M., et al. (2018). Phase 2 randomized cross-over trial of abiraterone + prednisone vs enzalutamide for patients with mCPRC: Results for 2nd-line therapy. J. Clin. Oncol., 36 (15), 5015a.10.1200/JCO.2018.36.15_suppl.5015
]Search in Google Scholar
[
Knipper, S., Beyer, B., Mandel, P., Tennstedt, P., Tilki, D., Steuber, T., Freafen, M. (2020). Outcome of patients with newly diagnosed prostate cancer with low metastatic burden treated with radical prostatectomy: A comparison to STAMPEDE arm H. World J. Urol., 38 (6), 1459–1464.10.1007/s00345-019-02950-031511970
]Search in Google Scholar
[
Knipper, S., Mandel, P., Graefen, M. (2019). Lokale Therapie beim fort-geschrittenen und metastasierten Prostatakarzinom. Uro-News, 23, 36–39.10.1007/s00092-019-2185-2
]Search in Google Scholar
[
Koo, K. C., Lee, J. S., Ha, J. S., Han, K. S., Lee, K. S., Hah, Y. S., Rha, K. H., Hong, S. J., Chung, B. H. (2019). Optimal sequencing strategy using docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant prostate cancer: Utilization of neutrophil-to-lymphocyte ratio. World J. Urol., 37 (11), 2375–2384.10.1007/s00345-019-02658-130734074
]Search in Google Scholar
[
Kretschmer, A., Todenhöfer, T. (2020). Systemische Therapie des fortgeschrittenen Prostatakarzinoms Urologe A., 59 (12), 1565–1576.10.1007/s00120-020-01381-9
]Search in Google Scholar
[
Kumar, J., Jazayeri, S. B., Gautam, S., Norez, D., Alam, M. U., Tanneru, K., Bazargani, S., Costa, J., Bandyk, M., Ganapathi, H. P., et al. (2020). Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: a systematic review and network meta-analysis. Urol. Oncol., 38 (11), 826–834.10.1016/j.urolonc.2020.03.022
]Search in Google Scholar
[
Kyriakopoulos, C. E., Chen, Y. H., Carducci, M. A., Liu, G., Jarrard, D. F., Hahn, N. M., Shevrin, D. H., Dreicer, R., Hussain, M., Eisenberger, M., et al. (2018). Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: Long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J. Clin. Oncol., 36 (11), 1080–1087.10.1200/JCO.2017.75.3657
]Search in Google Scholar
[
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015). PD-1 blockade in tumors with mismatch-repair deficiency. New Engl. J. Med., 372 (26), 2509–2520.10.1056/NEJMoa1500596
]Search in Google Scholar
[
Li, M. M., Datto, M., Duncavage, E. J., Kulkarni, S., Lindeman, N. I., Roy, S., Tsimberidou, A. M., Vnencak-Jones, C. L., Wolff, D. J., Younes, A., et al. (2017). Standards and guidelines for the interpretation and reporting of sequence variants in cancer: A joint consensus recommendation of the association for molecular pathology, American Society of Clinical Oncology, and College of American Pathologists. J. Mol. Diagn., 19 (1), 4–23.10.1016/j.jmoldx.2016.10.002
]Search in Google Scholar
[
Lotan, T, L., Tomlins, S. A., Bismar, T. A., Van der Kwast, T. H., Grignon, D., Egevad, L., Kristiansen, G., Pritchard, C. C., Rubin, M. A., Bubendorf, L. (2020). Report from the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular biomarkers in prostate cancer. Ann. J. Surg. Pathol., 44 (7), e15–e29.10.1097/PAS.0000000000001450
]Search in Google Scholar
[
Mottet, N., Cornford, P., van den Bergh, R. C. N., De Santis, M., Fanti, S., Gillessen, S., Grummet, J., Henry, A. M., Lam, T. B., Mason, M. D., et al. (2020). EAU – ESTRO – ESUR – SIOG Guidelines on Prostate Cancer. EAU Guidelines Office, Arnhem.
]Search in Google Scholar
[
Parker, C. C., James, N. D., Brawley, C. D., Clarke, N. W., Hoyle, A. P., Ali, A., Ritchie, A. W. S., Attard, G., Chowdhury, S., Cross, W., et al. (2018). Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): A randomised controlled phase 3 trial. Lancet, 392 (10162), 2353–2366.
]Search in Google Scholar
[
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O’Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013). Alpha emitter radium-223 and survival in metastatic prostate cancer. New Engl. J. Med., 369 (3), 213–223.10.1056/NEJMoa1213755
]Search in Google Scholar
[
Roach, M. 3rd, Hanks, G., Thames H. J., Schellhammer, P., Shipley, W. U., Sokol G. H., Sandler, H., et al. (2006). Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int. J. Radiat. Oncol. Biol. Phys. 65, 965–974.10.1016/j.ijrobp.2006.04.029
]Search in Google Scholar
[
Ryan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F., Sternberg, C. N., Miller, K., Logothetis, C. J., Shore, N. D., Small, E. J., et al. (2015). Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol., 16 (2), 152–160.10.1016/S1470-2045(14)71205-7
]Search in Google Scholar
[
Scher, H. I., Fizazi, K., Saad, F., Taplin, M. E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., Armstrong, A. J., et al. (2012). Increased survival with enzalutamide in prostate cancer after chemotherapy. New Engl. J. Med., 367 (13), 1187–1197.10.1056/NEJMoa120750622894553
]Search in Google Scholar
[
Smith, M. R., Fizazi, K., Sandhu, S. K., Kelly, W. K., Efstathiou, E., Lara, P., Yu, E.Y., George, D. J., Chi, K. N., Saad, F., et al. (2020). Niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Correlative measures of tumor response in phase II GALAHAD study. J. Clin. Oncol., 38 (6), 118.10.1200/JCO.2020.38.6_suppl.118
]Search in Google Scholar
[
Smith, M. R., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B. A., Graff, J. N., Olmos, D., Mainwaring, P. N., Lee, J. Y., Uemura, H. et al. (2018). Apalutamide treatment and metastasis-free survival in prostate cancer. New. Engl. J. Med., 378 (15), 1408–1418.10.1056/NEJMoa171554629420164
]Search in Google Scholar
[
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl. J. Med. 351 (15), 1502–1512.10.1056/NEJMoa04072015470213
]Search in Google Scholar
[
Thomas, C., Ohlmann, C. H. (2020) Combination therapy for metastatic hormone- sensitive prostate cancer: What? When? For whom? Urologe A., 59 (6), 665–672.10.1007/s00120-020-01189-7
]Search in Google Scholar
[
Tu, X., Chang, T., Nie, L., Qiu, S., Xu, H., Huang, Y., Bao, Y., Liu, Z., Yang, L., Wei, Q. (2019). Neuroendocrine carcinoma of the prostate: A sytematic review and pooled analysis. Urol. Int., 203, 383–390.10.1159/00049988330965328
]Search in Google Scholar
